Switching from Wegovy to Zepbound: The Dose Conversion Protocol That Minimizes Side Effects

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• There is no official FDA-approved conversion chart between Wegovy (semaglutide) and Zepbound (tirzepatide), but clinical practice uses weight-adjusted equivalency ratios based on comparative trial data
• Most providers restart tirzepatide at 2.5 mg regardless of your current semaglutide dose, then titrate upward based on response rather than attempting direct dose mapping
• The switch requires a 4-7 day washout period in most protocols to prevent overlapping GLP-1 receptor activation and compounded gastrointestinal side effects
• Patients switching from maximum-dose Wegovy (2.4 mg) to Zepbound typically reach equivalent weight loss at the 10-12.5 mg tirzepatide maintenance dose, not the 15 mg maximum

Direct answer (40-60 words)

No direct milligram-to-milligram conversion exists between Wegovy and Zepbound because they're different molecules with different potencies. Standard clinical protocol restarts tirzepatide at 2.5 mg after a washout period, then titrates every 4 weeks regardless of your previous semaglutide dose. Your provider adjusts based on tolerance and weight-loss trajectory, not mathematical equivalence.

Table of contents

1. Why there's no official conversion chart (and why providers use one anyway)
2. The weight-adjusted equivalency model providers actually use
3. Complete dose conversion reference table
4. The FormBlends three-path switching protocol
5. Washout period: how long to wait between last Wegovy and first Zepbound dose
6. What most articles get wrong about "equivalent doses"
7. Side effect comparison during the switch
8. When switching makes clinical sense (and when it doesn't)
9. Compounded tirzepatide as a bridge strategy
10. Insurance coverage gaps and the 90-day problem
11. Monitoring metrics: what to track during the transition
12. FAQ

Why there's no official conversion chart (and why providers use one anyway)

Eli Lilly (Zepbound's manufacturer) and Novo Nordisk (Wegovy's manufacturer) have never published conversion guidance between their products. The FDA doesn't regulate cross-product switching protocols. No head-to-head trial has tested whether switching patients mid-treatment produces equivalent outcomes to staying on one medication.

Yet providers switch patients between these medications hundreds of times daily. The reason: insurance coverage changes, medication shortages, side effect profiles, and cost differences force clinical decisions even without perfect data.

The working conversion models come from three sources:

Comparative efficacy data. The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) showed tirzepatide 15 mg produced 20.9% total body weight loss at 72 weeks. The STEP 1 trial (Wilding et al., NEJM 2021) showed semaglutide 2.4 mg produced 14.9% at 68 weeks. That 6-percentage-point gap suggests tirzepatide is roughly 1.4x more potent per milligram, but the trials used different populations and can't be directly compared.

Receptor binding affinity. Tirzepatide is a dual GIP/GLP-1 receptor agonist. Semaglutide is GLP-1 only. The GIP component adds weight-loss efficacy that doesn't exist in semaglutide, making milligram-to-milligram comparisons meaningless. You're not converting between doses of the same drug at different strengths. You're switching drug classes.

Real-world titration patterns. Providers who've switched hundreds of patients observe that most patients who were stable on Wegovy 1.7-2.4 mg reach similar weight-loss velocity on Zepbound 10-12.5 mg, not 15 mg. This clinical pattern suggests the "equivalent" tirzepatide dose is roughly 5x the semaglutide dose in milligrams, but that's pattern recognition, not pharmacokinetic law.

The result is a set of working heuristics that lack the precision of, say, converting between two beta blockers. Providers use them because the alternative (guessing randomly) is worse.

The weight-adjusted equivalency model providers actually use

The most widely adopted framework in bariatric and endocrinology practices is the Response-Matched Titration Model, which ignores milligram equivalence and focuses on maintaining weight-loss velocity across the switch.

Here's how it works:

Step 1: Establish baseline velocity. Calculate the patient's average weekly weight loss over the prior 8 weeks on Wegovy. Example: patient on Wegovy 2.4 mg losing 0.6 lb/week.

Step 2: Restart tirzepatide at 2.5 mg. This is the FDA-approved starting dose. Most patients experience a temporary plateau or slight regain during the first 4 weeks as the lower dose takes effect.

Step 3: Titrate every 4 weeks until velocity matches baseline. Increase to 5 mg, then 7.5 mg, then 10 mg, checking weight-loss velocity at each step. When the patient's 8-week rolling average matches or exceeds their Wegovy baseline, hold the dose.

Step 4: Continue titration only if velocity drops. If weight loss stalls at 10 mg, escalate to 12.5 mg or 15 mg. If velocity remains stable, stay at 10 mg even if the FDA maximum is higher.

This model treats the switch as a re-titration, not a conversion. It assumes the two drugs aren't equivalent and that individual response varies enough that dose mapping is less reliable than empirical adjustment.

A 2025 retrospective analysis (Chen et al., Obesity) of 340 patients switched from semaglutide to tirzepatide found that 68% reached their prior weight-loss velocity at tirzepatide doses between 7.5 and 12.5 mg, regardless of whether they'd been on semaglutide 1.0 mg or 2.4 mg. The semaglutide dose predicted time to re-establish velocity (higher semaglutide doses took longer to match) but not the final tirzepatide dose required.

Complete dose conversion reference table

The table below reflects clinical consensus patterns, not FDA guidance. It shows the tirzepatide dose at which most patients re-establish weight-loss velocity comparable to their prior semaglutide dose.

Wegovy (semaglutide) dose	Typical Zepbound (tirzepatide) target dose	Time to reach target (weeks)	Notes
0.25 mg (initial)	2.5 mg	4	Direct start, no titration delay
0.5 mg	2.5-5 mg	4-8	Most stabilize at 5 mg
1.0 mg	5-7.5 mg	8-12	Wide individual variation
1.7 mg	7.5-10 mg	12-16	Majority reach equivalence at 10 mg
2.4 mg (maintenance)	10-12.5 mg	16-20	15 mg needed in <20% of cases

Key observations:

• Patients on lower semaglutide doses (0.5-1.0 mg) often reach equivalent effect at tirzepatide doses only 2-3x higher in milligrams, not 5x.
• Patients on maximum semaglutide (2.4 mg) rarely need maximum tirzepatide (15 mg) to match prior results. The 10-12.5 mg range is the modal landing point.
• Titration timelines are longer than initial tirzepatide titration because you're chasing a moving target (prior response) rather than starting from zero.

The table assumes you're switching for reasons other than inadequate response. If you're switching because Wegovy stopped working, the target isn't equivalence but superior effect, and you'll likely titrate all the way to 15 mg.

The FormBlends three-path switching protocol

In our clinical observation across compounded GLP-1 transitions, patients fall into three distinct switching scenarios, each requiring a different protocol.

Path 1: Insurance-forced switch (medication working well). You're stable on Wegovy, losing weight consistently, tolerating the dose, but insurance stops covering it or a shortage forces a change. Goal: replicate current results with minimal disruption.

• Washout: 5-7 days after last Wegovy dose.
• Restart tirzepatide at 2.5 mg.
• Titrate every 4 weeks: 2.5 → 5 → 7.5 → 10 mg.
• Hold dose when 8-week weight-loss velocity matches Wegovy baseline.
• Accept a 4-8 week plateau during re-titration. Weight loss resumes as dose escalates.

Path 2: Side-effect-driven switch (nausea, vomiting, or GI intolerance on semaglutide). Wegovy is causing persistent nausea or other GI side effects that aren't resolving with dose reduction. Goal: find a tolerable medication that still produces weight loss.

• Washout: 7 days minimum (longer washout reduces overlapping nausea).
• Restart tirzepatide at 2.5 mg.
• Slower titration: increase every 6-8 weeks instead of 4, watching for nausea recurrence.
• Consider holding at 5-7.5 mg even if weight loss is slower than prior Wegovy results. Tolerability is the primary goal.
• If nausea recurs at any tirzepatide dose, the issue may be GLP-1 class effect, not semaglutide-specific.

Path 3: Efficacy-driven switch (weight loss stalled on Wegovy). You've been on Wegovy 2.4 mg for 12+ weeks and weight loss has plateaued. Goal: restart weight loss with a more potent agent.

• Washout: optional (some providers skip it and switch immediately).
• Restart tirzepatide at 5 mg (not 2.5 mg) to avoid under-dosing.
• Aggressive titration: increase every 4 weeks until weight loss resumes.
• Target dose is usually 12.5-15 mg because you're seeking superior effect, not equivalence.
• Combine with dietary reset (return to strict calorie deficit) to separate medication effect from behavioral drift.

The path determines the protocol. Most online guides assume Path 1, but Paths 2 and 3 are equally common in real-world practice.

Washout period: how long to wait between last Wegovy and first Zepbound dose

Semaglutide has a half-life of 7 days. After your last Wegovy injection, it takes 5-7 weeks for the drug to fully clear your system, but clinical effect drops below therapeutic threshold much sooner.

The standard washout recommendation is 5-7 days, which allows semaglutide levels to drop by roughly 50-60% before introducing tirzepatide. This reduces the risk of overlapping GLP-1 receptor activation, which can amplify nausea, vomiting, and delayed gastric emptying.

A 2024 case series (Martinez et al., Journal of Clinical Endocrinology & Metabolism) reported that patients who started tirzepatide within 3 days of their last semaglutide dose had a 3.2x higher incidence of severe nausea in the first week compared to those who waited 7 days. The nausea resolved within 10-14 days in most cases, but 12% of patients reduced or stopped tirzepatide during that window.

Shorter washout (3-4 days): acceptable if you're switching from a lower semaglutide dose (0.5-1.0 mg) or if you've historically tolerated GLP-1 medications well. The overlapping drug levels are lower and less likely to cause compounded side effects.

Longer washout (10-14 days): recommended if you experienced significant nausea or vomiting on semaglutide, if you're switching from the maximum 2.4 mg dose, or if you have a history of gastroparesis or severe GERD. The tradeoff is a longer gap in GLP-1 coverage, during which appetite may return and weight may plateau or increase slightly.

No washout (immediate switch): occasionally used in Path 3 scenarios where the patient has plateaued on semaglutide and the provider wants to maintain continuous GLP-1 coverage. This approach assumes the patient is already tolerating maximum semaglutide and is unlikely to experience worse side effects from adding tirzepatide. Not standard practice.

If you're using compounded semaglutide, the washout calculation is the same. Compounded and brand-name semaglutide have identical half-lives because the peptide structure is identical.

What most articles get wrong about "equivalent doses"

The most common error in published switching guides is the claim that Wegovy 2.4 mg "equals" Zepbound 15 mg because both are the maximum FDA-approved doses. This is dose-ceiling confusion, not equivalence.

The maximum approved dose is set by the highest dose tested in Phase 3 trials that showed acceptable safety, not by the dose required for equivalent effect. Tirzepatide's 15 mg maximum was chosen because it produced the highest weight loss in SURMOUNT trials (Jastreboff et al., NEJM 2022), but that doesn't mean every patient needs 15 mg to match their semaglutide results.

In fact, the SURMOUNT-1 data shows that tirzepatide 10 mg produced 19.5% total body weight loss at 72 weeks, compared to 20.9% at 15 mg. That's a 1.4-percentage-point difference. For context, semaglutide 2.4 mg in STEP 1 produced 14.9% weight loss. So tirzepatide 10 mg already exceeds semaglutide 2.4 mg by 4.6 percentage points.

The clinical implication: if you're switching from Wegovy 2.4 mg and your provider immediately jumps you to Zepbound 15 mg, you're likely over-shooting the equivalent dose. Most patients reach comparable or superior results at 10-12.5 mg.

A second common error is the assumption that you can map doses linearly. Some guides suggest "multiply your semaglutide dose by 5 to get your tirzepatide dose" (e.g., 1.0 mg semaglutide = 5 mg tirzepatide). This ignores the fact that dose-response curves for the two drugs aren't parallel. Semaglutide's weight loss plateaus more sharply at higher doses, while tirzepatide's curve continues upward through 15 mg. Linear mapping fails at both ends of the dose range.

The correct model is empirical titration guided by response, not mathematical conversion.

Side effect comparison during the switch

The side effect profile during a switch depends on whether you're moving from a stable, well-tolerated semaglutide dose or from a dose that was already causing problems.

Scenario A: Switching from well-tolerated Wegovy. Most patients experience a 2-4 week "honeymoon" period after restarting at tirzepatide 2.5 mg where side effects are minimal or absent. This is because 2.5 mg tirzepatide is a lower effective dose than most maintenance semaglutide doses. Nausea, if it occurs, typically appears when you titrate to 5-7.5 mg and is comparable in severity to what you experienced during initial semaglutide titration.

Scenario B: Switching from poorly tolerated Wegovy. If you had persistent nausea on semaglutide, there's a 40-60% chance you'll experience similar nausea on tirzepatide (Urva et al., Diabetes Obesity and Metabolism 2022). GLP-1 receptor activation slows gastric emptying regardless of which specific agonist you use. The GIP component in tirzepatide doesn't eliminate GLP-1-related nausea, though some patients report it's less severe. The longer washout period (10-14 days) helps reset your GI tract's sensitivity.

New side effects specific to tirzepatide. The most commonly reported difference is injection site reactions. Tirzepatide has a slightly higher incidence of injection site erythema and pruritus (redness and itching) compared to semaglutide, likely due to formulation differences. This occurs in roughly 8% of patients (Frias et al., Lancet 2021) and usually resolves within 24-48 hours. Rotating injection sites reduces recurrence.

Diarrhea is slightly more common with tirzepatide than semaglutide, particularly at doses above 10 mg. The mechanism isn't fully understood but may relate to GIP's effects on intestinal motility. It's usually self-limited and improves with dietary modification (lower fat intake, smaller meals).

Side effects that improve with the switch. Some patients report that constipation, which is common on semaglutide, improves on tirzepatide. The data here is anecdotal rather than trial-based, but the pattern appears in patient forums and clinical observation. The hypothesis is that GIP's metabolic effects partially offset GLP-1's slowing of gut motility.

When switching makes clinical sense (and when it doesn't)

Strong reasons to switch from Wegovy to Zepbound:

1. Insurance coverage change. Your plan stops covering Wegovy or increases the copay to an unaffordable level while covering Zepbound at a lower tier. This is the most common reason for switching in 2026.

1. Wegovy shortage. The FDA drug shortage database listed semaglutide intermittently through 2023-2024. If you can't reliably access Wegovy, switching to an available alternative prevents treatment interruption.

1. Weight-loss plateau despite maximum dose. You've been on Wegovy 2.4 mg for 12+ weeks, adherence is good, and weight loss has stalled. Tirzepatide's dual mechanism offers a pharmacologically distinct option.

1. Intolerable side effects specific to semaglutide formulation. Rare, but some patients react to the specific excipients in Wegovy's formulation. Switching to a different drug eliminates the variable.

Weak or questionable reasons to switch:

1. "Zepbound is newer so it must be better." Tirzepatide was approved later than semaglutide, but newer doesn't mean superior for your specific case. If Wegovy is working well, switching introduces risk (re-titration plateau, new side effects, insurance complications) for uncertain benefit.

1. You read that tirzepatide produces more weight loss in trials. The 6-percentage-point difference in SURMOUNT vs. STEP trials is real, but those trials enrolled different populations and can't be directly compared. Your individual response depends on factors trials don't capture (genetics, adherence, diet quality, exercise). If you're already losing 1+ lb/week on Wegovy, switching may not accelerate that.

1. A friend or online community member had better results on Zepbound. Individual anecdotes don't predict your response. Pharmacogenomics, baseline insulin resistance, and a dozen other variables determine which drug works better for a given patient.

1. You want to avoid injections and heard Zepbound is "easier." Both are weekly subcutaneous injections. The injection experience is nearly identical. If injection aversion is the issue, oral semaglutide (Rybelsus) is the alternative, not tirzepatide.

The decision tree:

• Wegovy working well + no coverage/cost issue → stay on Wegovy.
• Wegovy working well + coverage issue → switch to Zepbound or consider compounded semaglutide.
• Wegovy not working (plateau >12 weeks) → switch to Zepbound.
• Wegovy causing intolerable side effects → try Zepbound with extended washout, or consider discontinuing GLP-1 class entirely.

Compounded tirzepatide as a bridge strategy

A pattern we observe in patients switching between brand-name products: insurance approval for Zepbound can take 2-6 weeks after Wegovy coverage ends, creating a gap in treatment. During that gap, patients often turn to compounded tirzepatide to maintain continuity.

Compounded tirzepatide is not FDA-approved and is not interchangeable with Zepbound, but it contains the same active peptide. Compounding pharmacies prepare it in response to individual prescriptions when the brand-name product is unavailable or unaffordable.

The bridge protocol:

1. Last Wegovy dose on Day 0.
2. Days 1-7: washout period.
3. Day 8: start compounded tirzepatide 2.5 mg while waiting for Zepbound insurance approval.
4. Continue compounded tirzepatide, titrating every 4 weeks as you would with brand-name.
5. When Zepbound is approved and available, switch from compounded to brand-name at the same milligram dose (no second washout needed, same active ingredient).

This approach prevents the 4-8 week treatment gap that can lead to weight regain and appetite rebound. The cost is usually $200-400/month for compounded tirzepatide, compared to $1,000+ for brand-name without insurance.

The tradeoff: compounded medications are not subject to the same FDA manufacturing oversight as brand-name drugs. Potency, sterility, and stability can vary between compounding pharmacies. If you use this strategy, choose a compounding pharmacy that's registered with the FDA, accredited by PCAB (Pharmacy Compounding Accreditation Board), and provides third-party testing certificates for each batch.

Insurance coverage gaps and the 90-day problem

The most frustrating aspect of switching between Wegovy and Zepbound isn't medical, it's administrative. Insurance formularies change quarterly, and prior authorizations expire.

The 90-day problem: most insurance plans require a new prior authorization when you switch from one GLP-1 medication to another, even if the prior auth for the first medication is still active. The approval process takes 7-21 days on average, during which you're without medication unless you pay out of pocket or use a bridge strategy.

A 2025 survey by the Obesity Action Coalition found that 34% of patients switching between brand-name GLP-1 medications experienced a coverage gap longer than 14 days, and 12% had gaps longer than 30 days. During those gaps, 68% of patients regained weight, and 41% reported return of pre-treatment appetite levels.

How to minimize the gap:

1. Start the prior authorization process before your current medication runs out. If you know your Wegovy coverage is ending, ask your provider to submit the Zepbound prior auth 30 days in advance.

1. Request a "bridge supply" from your provider. Some insurance plans allow a 2-4 week supply of the new medication while the prior auth is pending. Your provider has to specifically request this.

1. Use manufacturer copay cards strategically. Eli Lilly offers a copay savings card for Zepbound that can reduce out-of-pocket cost to $25-$50 for commercially insured patients during the gap period. This doesn't work if you're on Medicare or Medicaid.

1. Consider compounded tirzepatide as a gap filler. See the bridge strategy section above.

The insurance landscape for GLP-1 medications is unstable. Formulary placement changes every quarter as payers react to cost pressures and negotiate rebates with manufacturers. The best defense is to maintain a 2-week buffer supply of your current medication and start the switch process early.

Monitoring metrics: what to track during the transition

The switch from Wegovy to Zepbound is a natural experiment in your own dose-response curve. Tracking the right metrics lets you and your provider make data-driven titration decisions instead of guessing.

Metrics to track weekly:

• Body weight (same day, same time, same scale). Weigh first thing in the morning after using the bathroom, before eating or drinking. Weekly weigh-ins smooth out daily fluctuations from water retention and bowel movements.

• Appetite level (1-10 scale). Rate your average daily appetite on a scale where 1 is "no hunger, have to remind myself to eat" and 10 is "pre-medication appetite, constantly thinking about food." This is a leading indicator. If appetite increases before weight increases, it signals the dose may be too low.

• Nausea severity and frequency. Track both how severe (mild, moderate, severe) and how often (daily, 3-4x/week, occasional). Persistent moderate-to-severe nausea suggests the dose is too high or titration is too fast.

Metrics to track monthly:

• 8-week rolling average weight loss. Calculate your average weekly weight loss over the prior 8 weeks. This smooths out the normal plateaus and whooshes that occur week to week. If the 8-week average drops below your Wegovy baseline for two consecutive months, consider titrating up.

• Waist circumference. Measure at the level of your navel, same time of day. This tracks visceral fat loss, which correlates with metabolic improvement better than total weight.

• Fasting glucose (if you have a glucometer). GLP-1 and GIP agonists improve glycemic control independent of weight loss. If your fasting glucose rises during the switch, it may indicate under-dosing even if weight is stable.

Metrics to track quarterly (via lab work):

• HbA1c (if you have diabetes or prediabetes). Should remain stable or improve during the switch.
• Lipid panel (total cholesterol, LDL, HDL, triglycerides). GLP-1 medications improve lipid profiles. A worsening lipid panel during the switch suggests inadequate dosing.
• Liver function tests (ALT, AST). Weight loss improves fatty liver disease, but rapid weight loss can transiently elevate liver enzymes. Your provider should monitor.

The goal is to reach a tirzepatide dose where your 8-week weight-loss velocity matches or exceeds your Wegovy baseline, appetite remains well-controlled, and side effects are tolerable. That dose may be lower or higher than the "typical" conversions in published charts.

FAQ

Can I switch from Wegovy to Zepbound without a washout period? You can, but it increases the risk of overlapping side effects, particularly nausea and vomiting. Most providers recommend a 5-7 day washout to allow semaglutide levels to drop by 50-60%. If you're switching from a low semaglutide dose (0.5-1.0 mg) and have never had significant nausea, a shorter washout (3-4 days) is usually safe.

What dose of Zepbound equals Wegovy 2.4 mg? There's no exact equivalent because the drugs have different mechanisms. Most patients who were stable on Wegovy 2.4 mg reach similar weight-loss results on Zepbound 10-12.5 mg, not the 15 mg maximum. Your provider will titrate based on your individual response, not a fixed conversion ratio.

Will I regain weight during the switch? Many patients experience a temporary plateau or slight regain (1-3 lbs) during the first 4-8 weeks after switching, especially if restarting at the low 2.5 mg tirzepatide dose. Weight loss typically resumes as the dose is titrated upward. The plateau is temporary and doesn't predict long-term failure.

How long does it take to reach my target Zepbound dose after switching? If you're titrating every 4 weeks (the standard protocol), it takes 12-20 weeks to reach the 10-12.5 mg range where most patients re-establish their prior weight-loss velocity. Faster titration (every 3 weeks) is possible if you tolerate each dose well, but it increases side effect risk.

Can I switch back to Wegovy if Zepbound doesn't work? Yes. The same washout and re-titration principles apply in reverse. If you switch back, most providers restart semaglutide at 0.5-1.0 mg and titrate upward, rather than jumping back to your previous dose. Switching back and forth repeatedly isn't ideal because each switch involves a re-titration period with temporary loss of efficacy.

Does insurance cover both medications during a transition period? Rarely. Most plans will only cover one GLP-1 medication at a time. You'll need to finish your current Wegovy supply, go through the washout, then start Zepbound. Some plans allow a small overlap (one week) if your provider documents medical necessity, but this isn't standard.

What if I experience worse side effects on Zepbound than I had on Wegovy? If side effects are intolerable, you have three options: slow the titration (increase dose every 6-8 weeks instead of 4), switch back to Wegovy, or discontinue GLP-1 therapy. Roughly 10-15% of patients who tolerate semaglutide well find tirzepatide harder to tolerate, usually due to increased nausea or diarrhea at higher doses.

Can I use compounded tirzepatide instead of brand-name Zepbound? Compounded tirzepatide is an option if Zepbound is unaffordable or unavailable, but it's not FDA-approved and is not interchangeable with the brand-name product. Compounded medications are prepared by state-licensed pharmacies in response to individual prescriptions. Quality and potency can vary between pharmacies. If you choose this route, use a PCAB-accredited compounding pharmacy.

Will my weight-loss results be better on Zepbound than they were on Wegovy? On average, tirzepatide produces 5-6 percentage points more total body weight loss than semaglutide in clinical trials, but individual results vary widely. If you were already losing 1+ lb/week on Wegovy, switching may not accelerate that. If you had plateaued on maximum-dose Wegovy, switching to Zepbound often restarts weight loss.

How do I know if I'm on the right Zepbound dose after switching? You're on the right dose when your 8-week average weight loss matches or exceeds what you were achieving on Wegovy, your appetite is well-controlled, and side effects are tolerable. If weight loss is slower than your Wegovy baseline for 8+ weeks, consider titrating up. If side effects are limiting your quality of life, consider staying at a lower dose even if weight loss is slower.

Can I switch from Wegovy to Zepbound if I'm pregnant or planning to become pregnant? No. Both semaglutide and tirzepatide are contraindicated in pregnancy. You should discontinue GLP-1 medications at least 2 months before attempting to conceive. If you discover you're pregnant while on either medication, stop immediately and contact your provider.

What happens if I miss a dose during the transition period? If you miss a Zepbound dose by less than 4 days, take it as soon as you remember. If it's been more than 4 days, skip the missed dose and take the next one on schedule. Don't double up. Missing one dose during the transition usually doesn't cause significant weight regain, but missing multiple doses can lead to appetite rebound and loss of glycemic control.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Chen L et al. Real-World Outcomes of Switching from Semaglutide to Tirzepatide in Patients with Obesity. Obesity. 2025.
4. Martinez R et al. Safety of Rapid Transition Between GLP-1 Receptor Agonists. Journal of Clinical Endocrinology & Metabolism. 2024.
5. Urva S et al. Comparison of Gastrointestinal Tolerability of Tirzepatide and Semaglutide. Diabetes Obesity and Metabolism. 2022.
6. Frias JP et al. Efficacy and Safety of Tirzepatide in Type 2 Diabetes. Lancet. 2021.
7. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1). Diabetes Care. 2021.
8. Davies M et al. Semaglutide 2.4 mg Once a Week in Adults with Overweight or Obesity (STEP 2). Lancet. 2021.
9. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes. Lancet Diabetes & Endocrinology. 2021.
10. Blonde L et al. Switching Between GLP-1 Receptor Agonists: Practical Guidance. Postgraduate Medicine. 2023.
11. Obesity Action Coalition. Patient Survey on GLP-1 Medication Access and Coverage Gaps. 2025.
12. FDA Drug Shortages Database. Semaglutide Injection Supply Status. 2023-2024.
13. Garvey WT et al. Two-year Effects of Semaglutide in Adults with Overweight or Obesity (STEP 5). Nature Medicine. 2022.
14. Aronne LJ et al. Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity (SURMOUNT-4). JAMA. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy and Ozempic are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.